T-cell acute lymphoblastic leukemia pediatric · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Daunorubicin, Pegaspargase, Vincristine, Dexamethasone Variant #01 Partial | — | R 12 738 | 28d | — | — | ~1 | ~R 12 738 indirect | — |
Daunorubicin, L-Asparaginase, Vincristine, Dexamethasone Variant #01 Partial | — | R 11 014 | 28d | — | — | ~1 | ~R 11 014 indirect | — |
DOLP Variant #16 Partial | — | R 9 311 | 42d | — | — | ~1 | ~R 9 311 indirect | — |
Doxorubicin, Methotrexate, Pegaspargase, Vincristine, Methylprednisolone Variant #01 Partial | — | R 4 392 | 28d | — | — | ~1 | ~R 4 392 indirect | — |
Daunorubicin, Pegaspargase, Vincristine, Prednisone Variant #11 Partial | — | R 2 355 | 42d | — | — | ~1 | ~R 2 355 indirect | — |
5 of 5 regimens shown